UGA Biopharma presents high performance cell lines at BIO Digital convention

Hennigsdorf, Germany: Leading-edge contract cell line developer, UGA Biopharma GmbH, will present its CHO cell line development platform for the production of biologics and biosimilars with titers from 4 to 7 g/L, along with their proprietary First CHOice® cell culture media and feeds at the BIO International Convention USA, now re-branded BIO Digital.

UGA will share details of its products and services using the online networking platforms provided by the organizers to allow the annual event to go ahead despite the coronavirus crisis.

Fast-track biologic production

UGA Biopharma will use the networking opportunities to present its advanced cell line development platforms and Ready-to-use biosimilar cell lines for GMP manufacturing, as for example Nivolumab or Pembrolizumab.

This will be UGA’s debut at the BIO series of events. The company will be represented online by its CEO, Dr. Lars Kober, and Business Development Manager, Dr. Marcel Nowak.

Need for COVID-19 response

Dr. Kober commented: “We are grateful to the BIO organization for their ingenuity and hard work in adapting this event so rapidly to allow it to take place despite COVID-19. The crisis means events like this are needed more urgently than ever.

“We will be reaching out to those interested in our CHO cell line development platform for the production of new biologics, and showing the benefits of our completely chemically defined First CHOice® cell culture media and feeds,” said Dr. Kober.

“We are also keen to talk about rapid contract cell line development across a whole range of biologics, including therapeutic antibodies, bispecific antibodies, fusion proteins, enzymes and hormones, where we can deliver advantages like high-titer yields, rigorous quality control, fast time-lines, high biosimilarity, traceability and a proven track record,” he concluded.

About UGA Biopharma

UGA Biopharma GmbH is an experienced contract developer of biologics and biosimilars with the capabilities to handle all necessary steps from cell line development and bioprocess development to the development of purification strategies and appropriate analytics.

The company supplies its customers in Germany and abroad from its headquarter in Hennigsdorf, near Berlin. Several clients have used UGA products in clinical trials or in products that have received market authorization.

UGA Biopharma GmbH CRO activities are centered on cell line development for biologics and biosimilars, specializing in the development of stable expressing CHO cell lines and cell media for the production of biologics and biosimilars for biopharmaceutical companies. Typical clients are biopharma manufacturers, research institutions (universities, research institutes, etc.) as well as start-ups and other CROs that need to outsource CLD, upstream, or downstream processing.

UGA’s mission is to fulfill customer requests, recognizing industry needs for high titer or fast delivery timelines, along with robust CHO cell lines. To this end, UGA can deliver high quality, and high titers, ranging from four to seven g/L, within four months of receiving the originator sequence.

UGA has also developed its proprietary First CHOice® cell culture media and feeds platform to boost the productivity of cell lines. Furthermore, UGA Biopharma GmbH offers ready-to-use biosimilar cell lines, which allow clients interested in biosimilar development fast track access to a highly biosimilar cell line.

Further information at: www.ugabiopharma.com

About BIO USA 2020

The 27th Anniversary BIO International Convention USA (BIO USA 2020) has been repurposed and rebranded BIO Digital 2020 to meet the new realities imposed by the COVID-19 pandemic and its demands for social distancing.

The event will be staged entirely online, using forums, webinars and video conferencing technology to allow the same networking and knowledge sharing benefits as the ‘live’ event.

Once again, BIO will be a five-day event, opening June 8, that will provide a week of intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships.

The 2020 event will feature a Coronavirus Resources hub that will include latest information from government agencies, NGOs, and other expert organizations, a Coronavirus Hub for knowledge sharing on COVID-19 treatments, vaccines, and diagnostics and Patient Support Programs available from companies and patient advocacy groups during the coronavirus pandemic.

BIO Digital is organized by the Washington DC-based Biotechnology Innovation Organization with more information at: http://convention.bio.org/